Roche has extended its offer's acceptance period twice, with the current period running until April 20. The company has also claimed it is willing to consider "other options" if the deal does not go through over price. Roche has set its sights on Illumina to expand its offering of personalized medicines. Illumina, which makes gene-decoding machines, would be an asset for Roche in terms of developing personalized drugs and therapies. The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.-- Written by Brittany Umar.